Personalis Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Personalis (Nasdaq: PSNL), a leader in advanced genomics for precision oncology, has announced the granting of a non-qualified stock option to its new Executive Director of Market Access & Reimbursement. The Compensation Committee of the Board of Directors approved this grant on August 15, 2024, under the company's 2020 Inducement Plan.
The stock option allows for the purchase of 75,000 shares of Personalis' common stock at an exercise price of $5.07 per share, equal to the closing price on the grant date. The option vests over four years, with 25% vesting after one year and the remainder vesting monthly over the following three years, subject to continued service.
Personalis (Nasdaq: PSNL), leader nella genomica avanzata per l'oncologia di precisione, ha annunciato l'assegnazione di un'opzione su azioni non qualificata al suo nuovo Direttore Esecutivo per l'Accesso al Mercato e il Rimborso. Il Comitato per la Compensazione del Consiglio di Amministrazione ha approvato questa concessione il 15 agosto 2024, nell'ambito del piano di incentivazione del 2020 dell'azienda.
L'opzione su azioni consente l'acquisto di 75.000 azioni ordinarie di Personalis a un prezzo di esercizio di $5,07 per azione, corrispondente al prezzo di chiusura nella data di concessione. L'opzione matura in quattro anni, con il 25% che matura dopo un anno e il restante che matura mensilmente nei successivi tre anni, subordinato alla continuazione del servizio.
Personalis (Nasdaq: PSNL), un líder en genómica avanzada para la oncología de precisión, ha anunciado la concesión de una opción de acciones no calificada a su nuevo Director Ejecutivo de Acceso al Mercado y Reembolso. El Comité de Compensación de la Junta Directiva aprobó esta concesión el 15 de agosto de 2024, bajo el Plan de Incentivos de 2020 de la compañía.
La opción de acciones permite la compra de 75,000 acciones ordinarias de Personalis a un precio de ejercicio de $5.07 por acción, que es igual al precio de cierre en la fecha de concesión. La opción se consolida durante cuatro años, con el 25% consolidándose después de un año y el resto consolidándose mensualmente durante los siguientes tres años, sujeto a la continuidad del servicio.
Personalis (Nasdaq: PSNL)는 정밀 종양학을 위한 첨단 유전체학 분야의 선두주자로서, 시장 접근 및 환급을 담당하는 새롭게 선임된 전무 이사에게 비등록 주식 옵션을 부여했다고 발표했습니다. 보상 위원회는 회의 날짜인 2024년 8월 15일에 이 부여를 승인을 했으며, 이는 회사의 2020년 유인 계획에 따른 것입니다.
이 주식 옵션은 75,000주의 Personalis 보통주를 주당 $5.07의 행사가격으로 구매할 수 있도록 허용합니다. 이는 부여일의 종가와 동일합니다. 이 옵션은 4년에 걸쳐 성과가 발생하며, 1년 후 25%가 성과가 발생하고, 나머지는 이후 3년 동안 매월 성과가 발생합니다. 이는 지속적인 서비스의 조건을 따릅니다.
Personalis (Nasdaq: PSNL), un leader dans la génomique avancée pour l'oncologie de précision, a annoncé l'octroi d'une option d'achat d'actions non qualifiée à son nouveau Directeur Exécutif de l'Accès au Marché et du Remboursement. Le Comité de Rémunération du Conseil d'Administration a approuvé cet octroi le 15 août 2024, dans le cadre du Plan d'Incitation de 2020 de la société.
L'option d'achat permet d'acquérir 75 000 actions ordinaires de Personalis à un prix d'exercice de 5,07 $ par action, correspondant au prix de clôture à la date d'octroi. L'option se libère sur une période de quatre ans, avec 25 % se libérant après un an et le reste se libérant mensuellement au cours des trois années suivant, sous réserve de la continuité du service.
Personalis (Nasdaq: PSNL), ein führendes Unternehmen in der fortschrittlichen Genomik für Präzisionsonkologie, hat die Vergabe einer nicht qualifizierten Aktienoption an seinen neuen Geschäftsführer für Marktzugang und Rückerstattung angekündigt. Das Vergütungskomitee des Vorstands hat diese Vergabe am 15. August 2024 im Rahmen des Unternehmensplans von 2020 genehmigt.
Die Aktienoption ermöglicht den Erwerb von 75.000 Aktien der Stammaktien von Personalis zu einem Ausübungspreis von 5,07 $ pro Aktie, was dem Schlusskurs am Tag der Vergabe entspricht. Die Option wird über einen Zeitraum von vier Jahren fällig, wobei 25% nach einem Jahr fällig werden und der Rest monatlich über die nächsten drei Jahre fällig wird, vorbehaltlich der Fortsetzung des Dienstes.
- Personalis is attracting new talent with stock options as inducement
- The company is expanding its executive team with a focus on market access and reimbursement
- None.
The 2020 Inducement Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee, or non-employee director, of Personalis, as an inducement material to such individual’s entering into employment with Personalis, pursuant to Rule 5635(c)(4) of the Nasdaq Listing Rules. Personalis is making this announcement as required by Nasdaq rules.
The inducement stock option granted on August 15, 2024 has an exercise price of
About Personalis, Inc.
At Personalis, we are transforming the active management of cancer through breakthrough personalized testing. We aim to drive a new paradigm for cancer management, guiding care from biopsy through the life of the patient. Our highly sensitive assays combine tumor-and-normal profiling with proprietary algorithms to deliver advanced insights even as cancer evolves over time. Our products are designed to detect minimal residual disease (MRD) and recurrence at the earliest timepoints, enable the selection of targeted therapies based on ultra-comprehensive genomic profiling, and enhance biomarker strategy for drug development. Personalis is based in
View source version on businesswire.com: https://www.businesswire.com/news/home/20240819610812/en/
Investor Relations Contact:
Caroline Corner
investors@personalis.com
415-202-5678
Media:
pr@personalis.com
Source: Personalis, Inc.
FAQ
What stock option grant did Personalis (PSNL) announce on August 15, 2024?
What is the exercise price of the stock option granted by Personalis (PSNL) on August 15, 2024?
How does the vesting schedule work for the stock option granted by Personalis (PSNL)?
What is the purpose of Personalis' (PSNL) 2020 Inducement Plan?
